Synapse - Center for Hematologic Malignancies

Results (13553)

Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL)

Meeting Abstract

Stathis, A.; Maddocks, K. J.; Flinn, I.; Mejia, A.; Palomba, M. L.; Zildjian, S.; Murphy, M.; Deckert, J.; Ruiz-Soto, R.; Freedman, A.
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Risk-based treatment for nonrhabdomyosarcoma soft tissue sarcomas (NRSTS) in patients under 30 years of age: Children's Oncology Group study ARST0332

Meeting Abstract

Spunt, S. L.; Million, L.; Anderson, J. R.; Coffin, C. M.; McCarville, B.; Randall, R. L.; Parham, D.; Kao, S. C.; Hayes-Jordan, A. A.; Wolden, S. L.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Predictors of overall survival in patients diagnosed with desmoplastic small round cell tumor (DSRCT)

Meeting Abstract

Shoushtari, A. N.; Qin, L. X.; Kuk, D.; Magnan, H. D.; Modak, S.; Wolden, S. L.; Cho, E. J.; Pallos, V.; Grubman, O.; Viny, A. D.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial

Meeting Abstract

Sharman, J. P.; Coutre, S. E.; Furman, R. R.; Cheson, B. D.; Pagel, J. M.; Hillmen, P.; Barrientos, J. C.; Zelenetz, A. D.; Kipps, T. J.; Flinn, I.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Clinical and histologic characterization of dermatologic adverse events front the pan-PI3K inhibitor buparlisib (BKM-120)

Meeting Abstract

Schindler, K.; Abraham, R.; Shah, P. D.; Chandarlapaty, S.; Paik, P. K.; Bell-Mcguinn, K.; Bajorin, D. F.; Mellinghoff, I. K.; Younes, A.; Gounder, M. M.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia

Meeting Abstract

Schiller, G. J.; Tallman, M. S.; Goldberg, S. L.; Perl, A. E.; Marie, J. P.; Martinelli, G.; Larson, R. A.; Russell, N.; Trone, D.; Gammon, G.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Circulating tumor cells (CTCs) and LDH as prognostic factors in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing during or following docetaxel treated in the orteronel phase 3 ELM-PC 5 trial

Meeting Abstract

Scher, H. I.; Fizazi, K.; Lee, C.; Maclean, D.; Tejura, B.; Webb, I. J.; Borgstein, N.; Dreicer, R.
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Graded potency of chimeric antigen receptor (CAR)-engineered T cells for cancer immunotherapy

Meeting Abstract

Sadelain, M.; Condomines, M.; Zhao, Z.; Brentjens, R. J.; Riviere, I.
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Targeting reciprocal feedback inhibition in the clinic: ARN509 and PI3K pathway inhibition in patients with metastatic castration-resistant prostate cancer (mCRPC)

Meeting Abstract

Rathkopf, D. E.; Carver, B. S.; Chen, Y.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Autio, K. A.; DeNunzio, M.; Sawyers, C. L.; Scher, H. I.
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

An open-label, phase 1b, dose-escalation study (CA180-373) of dasalinib plus itivollimab, an investigational anti-programmed cell death 1 (PD-1) antibody, in patients (pts) with previously treated chronic myeloid leukemia (CML)

Meeting Abstract

Porkka, K.; Mauro, M. J.; Lipton, J. H.; Mahon, F. X.; Strauss, L. C.; Geese, W. J.; Kroog, G. S.; Mustjokl, S.
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save